The emerging role of neuroimaging in psychiatry: Characterizing treatment-relevant endophenotypes

American Journal of Psychiatry

Volumn 164, Issue 5, 2007, Pages 697-699

  Phillips, Mary L ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VENLAFAXINE;

BEHAVIOR THERAPY; COGNITION; COGNITIVE THERAPY; DISEASE CLASSIFICATION; EDITORIAL; HUMAN; MAJOR DEPRESSION; NEUROIMAGING; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOTHERAPY; TREATMENT RESPONSE;

EID: 34249334312     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.2007.164.5.697     Document Type: Editorial

References (14)

1. Charney DS, Barlow DH, Botterton K, Cohen JD, Goldman D, Gur RE, Lin K-M, Lopez JF, Meador-Woodruff JH, Moldin SO, Nestler EJ, Waton SJ, Zalcman SJ: Neuroscience research agenda to guide development of a pathophysiological based classification system, in A Research Agenda for DSM-V. Edited by Kupfer DJ, First MB, Regier DA. Arlington, Va, American Psychiatric Publishing, 2002
2. Hasler G, Drevets WC, Gould TD, Gottesman II, Manji HK: Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry 2006; 60:93-105
3. Hasler G, Drevets WC, Manji HK, Charney DS: Discovering endophenotypes for major depression. Neuropsychopharmacology 2004; 29:1765-1781
4. Phillips ML, Frank E: Redefining bipolar disorder: toward DSM-V. Am J Psychiatry 2006; 163:1135-1136
5. Phillips ML, Drevets WC, Rauch SL, Lane RD: The neurobiology of emotion perception, I: towards an understanding of the neural basis of normal emotion perception. Biol Psychiatry 2003; 54:504-514
6. Brody AL, Saxena S, Silverman DH, Alborzian S, Fairbanks LA, Phelps ME, Huang SC, Wu HM, Maidment K, Baxter LR Jr: Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res 1999; 91:127-139
7. Goldapple K, Segal Z, Garson C, Lau M, Bieling P, Kennedy S, Mayberg H: Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 2004; 61:34-41
8. Holthoff VA, Beuthien-Baumann B, Zundorf G, Triemer A, Ludecke S, Winiecki P, Koch R, Fuchtner F, Herholz K: Changes in brain metabolism associated with remission in unipolar major depression. Acta Psychiatr Scand 2004; 110:184-194
9. Kennedy SH, Evans KR, Kruger S, Mayberg HS, Meyer JH, McCann S, Arifuzzman AI, Houle S, Vaccarino FJ: Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 2001; 158:899-905
10. Little JT, Ketter TA, Kimbrell TA, Dunn RT, Benson BE, Willis MW, Luckenbaugh DA, Post RM: Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biol Psychiatry 2005; 57:220-228
11. Martin SD, Martin E, Rai SS, Richardson MA, Royall R: Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Arch Gen Psychiatry 2001; 58:641-648
12. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA: Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 2000; 48:830-843
13. Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL, Silva JA, McGinnis S, Glass TG, Martin CC, Fox PT: Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997; 8:1057-1061
14. Siegle GJ, Carter CS, Thase ME: Use of fMRI to predict recovery from unipolar depression with cognitive behavior therapy. Am J Psychiatry 2006; 163:735-738